drugset
drugset / Trial / NCT03044379

Dapivirine Gel Rectal Safety and PK Study

NCT03044379 ↗

Phase 1 Withdrawn International Partnership for Microbicides, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

Dapivirine Gel Rectal Safety and PK Study

Timeline

Start
2015-09-29
Primary completion
2017-09
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator dapivirine Small molecule 0.05 % Rectal

Indications

HIV infectious disease